Latest News and Press Releases

Allegedly, Lineage’s IPO filings misrepresented business trends; post-IPO, destocking, leaner inventories, and oversupply drove its stock down ~50%.

Bid procedure, 2025-09-26BondsSWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01Bid date2025-09-26Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered...

Flywire allegedly overstated growth and downplayed visa impacts; weak results and guidance cuts led to downgrades and a 37% stock drop.

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5,...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sable Offshore To Contact Him Directly To Discuss Their Options If you purchased...

Allegedly, Lockheed Martin misled investors on internal controls and contract risks, later revealing $3.9B in program losses that drove sharp share decline

Vikk AI named to AWS–Meta Llama program, 1 of 33 startups chosen from 1,000+, to build first predictive legal analytics engine on Llama + AWS.

RxSight allegedly overstated product demand while facing adoption issues, then cut guidance and revealed weak sales, causing shares to plunge 38%.

Allegedly, defendants overstated IGNYTE trial prospects despite issues that led the FDA to deem it inadequate, misleading investors and causing losses.

Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and...